We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
Total approvals
Agencies
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No approval data available
• The FDA has approved omidubicel for patients with blood cancers requiring allogeneic hematopoietic stem cell transplant (HSCT). • A phase 3 trial showed omidubicel significantly reduced the median time to neutrophil engraftment compared to standard umbilical cord blood (UCB) grafts. • Omidubicel offers a new option for stem cell source, potentially improving outcomes for patients ineligible for traditional transplants. • The approval underscores the FDA's commitment to innovative therapies for life-threatening cancers, providing a new treatment option.
